Frederico Silva Castelo Branco, Angelo C. Pinto and Núbia Boechat Pages 2808 - 2849 ( 42 )
Tuberculosis (TB) is a serious public health issue, particularly in underdeveloped and developing countries. Furthermore the first-line anti-TB treatments were established over 40 years ago, multidrug-resistant Mycobacterium tuberculosis strains have been developed and the risk of coinfection with AIDS virus has highlighted this disease as a global emergency. The urgent need for more effective treatments against multidrug-resistant strains compatible with anti-AIDS drugs has prompted industries, governments and non-governmental agencies to pursue new drugs. In this study, we update the portfolio listed at Stop TB Partnership, present the biological activities as well as structure-activity relationship for these drugs and thoroughly discuss the synthetic methodologies used to produce these drugs.
Tuberculosis, chemistry, medicinal chemistry, novel compounds, clinical trial, Mycobacterium tuberculosis.
Fundação Oswaldo Cruz (FIOCRUZ), Instituto de Tecnologia em Fármacos (Farmanguinhos), Departamento de Síntese de Fármacos, Laboratório de Síntese 1, Rua Sizenando Nabuco, 100, Manguinhos, CEP: 21041-250 - Rio de Janeiro, RJ – Brasil.